Canavan Disease (CD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Canavan Disease (CD) Market Outlook
Thelansis’s “Canavan Disease (CD)
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Canavan Disease (CD) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Canavan
Disease (CD) Overview
Canavan
disease (CD) is a genetic degenerative brain disease caused by a lack of the
enzyme aspartoacylase (ASPA). N-acetylaspartic acid builds up in the brain and
other body parts when ASPA activity is lost. CD is diagnosed by detecting
elevated NAA in urine, blood, or the brain by proton MR spectroscopy and ASPA
mutation analysis. Insufficient myelination and progressive spongy degeneration
of the brain’s white matter characterize the disease histologically. While not
all Canavan disease (CD) patients had epilepsy in their early years, seizure
prevalence increased over the first decade, with all CD patients having
seizures by ten. Multiple antispasmodic or antiepileptic drugs are frequently
required to treat neurological symptoms such as seizures and spasticity.
Canavan disease (CD) is caused by mutations in the ASPA gene (17p13.3), which
codes for the aspartoacylase enzyme. Numerous mutations have been discovered,
and enzymatic activity is either low or non-existent as a result.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment